ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Novartis at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Novartis takes part in 3 sessions at ESMO 2026 in Madrid, and exhibits at Booth 1059. Its sessions focus on targeted radioligand treatment for prostate cancer and treatment choices for hormone-receptor-positive breast cancer. They also cover monitoring kidney safety during cancer radioligand therapy trials.
| Organization | ESMO 2026 Attendance |
|---|---|
Swiss pharmaceutical company whose oncology medicines include ribociclib for breast cancer and radioligand therapies. | Booth Exhibiting at Booth 1059 Poster Fri Oct 23 13:00–15:00 Renal safety monitoring in oncology radioligand therapy trials Nursing & supportive care Satellite Sat Oct 24 13:00–14:30 Novartis - PSMA-targeted RLT in Prostate Cancer: Present and future Genitourinary cancers Satellite Mon Oct 26 13:00–14:30 |
Find decision makers at Novartis
Tell us what you sell and we’ll find the people at Novartis most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction